Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma [4]

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1429-1430

  Nathan, P D ^a   Gore, M E ^a   Eisen, T G ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CORTICOSTEROID; RECOMBINANT ALPHA2A INTERFERON; THALIDOMIDE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HUMAN; KIDNEY METASTASIS; LETTER; MALE; NEUROTOXICITY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TINGLING; VISUAL DISORDER;

EID: 0036499274     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.5.1429     Document Type: Letter

References (4)

1. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
2. The treatment of advanced renal cell cancer with high-dose oral thalidomide
3. Antitumor activity of thalidomide in refractory multiple myeloma
4. Thalidomide in cancer: Potential uses and limitations